CLDN3 and neoplasm: In the NCI-H1781 and MCF7 models with high expression of both EpCAM and CLDN3, BsADC 3 demonstrated more potent anti-tumor activity than the EpCAM parental monoclonal ADC (Fig. 6A and B).